What’s driving Hepion Pharmaceuticals, Inc.’s (NASDAQ:HEPA) share price on post-market sessions?

CYTO Stock
CYTO Stock

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)stock surged 24.52% to $2.59 in the late hours last night after its Topline results have been announced from the Phase’s low dose cohort 2a ‘AMPITION’ clinical trial of CRV431, a novel cyclophilin inhibitor orally administered once daily.Phase 2a study of CRV431 is continuing at a higher dose of 225 mg, with CRV431 patient dosing expected in Q1-2021.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

A CRV431 study called the AMBITION trial will be conducted among patients with moderate-to-severe fibrosis and NASH evidence.Researchers at 10 U.S. sites are administering 75 mg of CRV431 once-daily for 28 days in this study. An ongoing second cohort of 225 mg CRV431 (high dose) is being administered. We expect to have final results from both dosing cohorts once the high dose group has completed active dosing, followed by a 14-day observation period.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More


Please enter your comment!
Please enter your name here